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Introduction: Cardiac amyloidosis is a rare condition characterized by the deposition of
well-structured protein fibrils, proteoglycans, and serum proteins as amyloid. Recent work
has shown that it may be possible to use 18F-Florbetapir to image cardiac amyloidosis.
Current methods for assessment include invasive biopsy techniques. This work enhances
foundational work by Dorbala et al. by developing a routine imaging and analysis protocol
using 18F-Florbetapir for cardiac amyloid assessment.
Methods: Eleven patients, three healthy controls and eight myloid positive patients, were
imaged using 18F-Florbetapir to assess cardiac amyloid burden. Four of the patients were
also imaged using 82Rb-Chloride to evaluate possible 18F-Florbetapir retention because
of reduced myocardial blood flow. Quantitative methods using modeling, SUVs and SUV
ratios were used to define a new streamlined clinical imaging protocol that could be used
routinely and provide patient stratification.
Results:Quantitative analysis of 18F-Florbetapir cardiac amyloid data were compiled from
a 20-min listmode protocol with data histogrammed into two static images at 0–5, 10–15,
or 15–20min. Data analysis indicated the use of SUVs or ratios of SUVs calculated from
regions draw in the septal wall were adequate in identification of all healthy controls from
amyloid positive patients in this small cohort. Additionally, we found that it may be possible
to use this method to differentiate patients suffering from AL vs. TTR amyloid.
Conclusion: This work builds on the seminal work by Dorbala et al. by describing a short
18F-Florbetapir imaging protocol that is suitable for routine clinical use and uses a simple
method for quantitative analysis of cardiac amyloid disease.
Keywords: cardiac, amyloidosis, amyloid, PET/CT, Florbetapir
1. Introduction
Cardiac amyloidosis is a rare condition characterized by the deposition of well-structured protein
fibrils, proteoglycans, and serum proteins as amyloid (1). The most common forms result from the
deposition of monoclonal immunoglobulin light chains (AL amyloidosis) or transthyretin, either
wild type (wtATTR) or mutant (ATTR) protein (2). The majority of patients with AL and ATTR
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develop systemic amyloidosis involving all visceral organs, par-
ticularly the liver, spleen, kidneys, and heart in patients with
AL, and peripheral nerves and heart in patients with ATTR.
Cardiac amyloidosis described as early as 1936 (3), typically
remains un-diagnosed until the deposits become extensive, pri-
marily because patients have a long asymptomatic phase and
present with common and non-specific symptoms that can range
from decreased appetite to gastrointestinal problems (4). Patients
with advanced cardiac involvement often present with symp-
toms of cardiomyopathy, such as shortness of breath (5). There-
fore, the disease is often initially misdiagnosed as a restrictive
cardiomyopathy, failure, e.g., associated with diabetes, without
amyloid involvement (6). Misdiagnosis may result in improper
patient management and a delay in appropriate patient care and
intervention.
Prognosis for patients with amyloidosis and cardiac involve-
ment is generally poor with median survival rates at diagnosis
of 5–6months for AL patients and 3–5 years for ATTR patients
(7, 8). Improved therapeutic strategies for the prevention of AL
and ATTR amyloid are being developed. Furthermore, novel
immunotherapies for amyloid removal are in clinical trial and
may provide new options for patients with amyloidosis (9). The
definitive diagnosis of systemic amyloidosis generally requires a
sub-cutaneous fat biopsy followed by Congo red staining of the
material amyloid is visible as blue–green birefringent material
when the slide is viewed microscopically under cross-polarized
illumination. Cardiac involvement is often identified by changes
in the serum levels of brain natriuretic peptide (10) as well as
the presence of interventricular thickening seen following ultra-
sound and/or magnetic resonance (MR) imaging (11). Although
useful, neither of these techniques are amyloid specific nor pro-
vide quantitative data on amyloid load. To this end, molecular
imaging strategies for detecting cardiac amyloidosis have been
applied but are not widely adopted outside of specialized amyloid
clinics (12). Gamma scintigraphic imaging with 99mTc-labeled
3,3-diphosphono-1,2 propanodicarboxylic acid (99mTc-DPD) can
provide accurate imaging of ATTR cardiac amyloid, but not car-
diac AL or TTR amyloid deposits in organs other than the heart
(13). 99mTc-labeled aprotinin has been used to image cardiac
amyloidosis in patients with AL and ATTR (14), but is not widely
used since the withdrawal of bovine aprotinin from the market
(15, 16). Anatomic imaging using echocardiography or magnetic
resonance imaging can be effectively used to determine the extent
of the amyloid involvement in themyocardium, but is non-specific
for disease etiology (17, 18).
Recent studies have shown that cardiac amyloidosis can be
detected using 11C-labeled Pittsburgh Compound B (11C-PIB);
however, parametric imaging was required and amyloid in other
visceral organs was not imaged (19). This work, although clearly
showing potential benefits, is limited for general application by a
number of compounding factors. More recently, small molecule
radiotracers used for detecting A amyloid in the brains of patients
with Alzheimers disease have been validated and approved by the
US Food and Drug Administration (20).
Dorbala et al. have provided the foundational work assess-
ing the potential role of 18F-Florbetapir (18F-AV45, Amyvid) in
imaging cardiac amyloid patients (21). They show that using a
30–60min scan time and parametric analysis, patients can be
suitably diagnosed and staged. Our work builds upon these results
through the development of a standardized imaging protocol of
approximately 20min and through the development of simpli-
fied analysis mechanisms to provide a quantitative assessment of
cardiac amyloid in patients (22, 23). We also assess the role of car-
diac perfusion in cardiac amyloid patients to determine whether
18F-Florbetapir imaging results could potentially be altered by
perfusion phenomenon.
2. Materials and Methods
2.1. Patient Population
Written informed consent for all patients was obtained under
two protocols approved by the University of Tennessee Institu-
tional Review Board (#3420 and #3841). Eight subjects, three
with ATTR and five with AL amyloid, were recruited for this
study. Disease was confirmed in accordance with criteria estab-
lished for the diagnosis of cardiac amyloidosis (24) using endomy-
ocardial biopsy or cardiac magnetic resonance imaging (MRI)
with tissue biopsy. Three healthy, control subjects (HC) were
recruited and imaged by using MRI to verify the absence of car-
diac amyloidosis. All patients were imaged using 18F-Florbetapir.
Three of the eight cardiac amyloid patients and one HC were
imagedwith rubidium chloride (82Rb-chloride) to assessmyocar-
dial perfusion. Additional details regarding clinical character-
istics of the patient recruited into this study can be found in
Table 1.
2.2. 18F-Florbetapir PET/CT Imaging
Patients were imaged on either a Biograph 6 TruePoint PET/CT or
a Biograph 64mCT Flow (Siemens Medical Solutions USA, Inc.).
Each subject was placed on the imaging table and injected with
10mCi of 18F-Florbetapir 10–15 s after the start of listmode data
acquisition. Image datawere acquired at a single-bed positionwith
the patient heart in the center of the field of view. PET data were
acquired for 30min based on findings from previous work (22). A
low-dose CT (120 kVp, with variablemAs) was acquired for rough
anatomical localization and attenuation and scatter correction.
CT data were reconstructed using a 512 512 image matrix with
1.37mm isotropic voxels and 5mm slice thickness.
PET data were histogrammed into 35 frames for dynamic anal-
ysis (10 frames of 10 s each, 10 frames of 30 s each, 10 frames of 60 s
each, 3 frames of 255 s each) as well as into single static sinograms
for reconstruction. PET data were reconstructed usingOSEM iter-
ative reconstruction algorithms to reconstruct a 200 200 image
matrix with 2.67mm isotropic voxel and a 2mm slice thickness.
All PET data were reconstructed with point spread function reso-
lution recovery (HDPET, Siemens Medical Solutions USA, Inc.)
applied.
A complete outline of the clinical protocol is provided in the
Section 3.
2.3. 18F-Florbetapir Image Analysis
Regions of interest (ROIs) were drawn over the left and right ven-
tricularmyocardium, blood pool, and portions of the liver. Details
regarding these regions are described below. Similar to Dorbala
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TABLE 1 | Patient data for amyloid positive and healthy controls.
Patient type Treatment IVS Rb PET/CT Ejection fraction Biopsy or cMRI BNP
TTR Dolobid 1.8 N/A Echo: <50% Heart: TTR+ 554
cMRI: 55% MRI: +
TTR SCT 2002 1.9 N/A Echo: 55% Fat aspirate: apo A4 706
cMRI: +
Cntrl N/A 1.1 N/A Echo: <60% N/A N/A
TTR None 1.7 N/A Echo: <65% Fat aspirate: TTR+ 38
cMRI: +
AL Velcade 1.8 Normal Echo: <65% Omentum: + 72
Rb: 53% cMRI: +
AL None 1.4 N/A N/A Fat aspirate: 1+ 508
TTR Dolobid 2.2 N/A Echo: 45% Heart: TTR+ 515
Cntrl N/A 1.1 N/A Echo: 60% N/A N/A
Cntrl N/A 0.9 Normal Echo: <60% N/A N/A
Rb: 73%
AL Cyclosporine 1.3 Normal Echo: <60% Kidney: 3+ 501
Velcade Rb: 60% cMRI: +
Dexamethasone
AL Velcade 0.7 Normal Echo: 67% Kidney: + 563
Dexamethasone Rb: 59% cMRI: +
et al. standard uptake values (SUVs), descriptive statistics, and
time activity curves (TACs) were generated for each ROI. Left and
right ventricle uptake was compared for each population to assess
any differences. TACs were analyzed for each ROI and data were
fit to multi-exponentials for basic kinetic assessment of uptake
and washout rates. Quantitative values were compared between
control and disease populations.
Data were assessed in four ways:
 First: SUVs were calculated for ROIs drawn in the septal wall
(1 cc volume) and near the dome of the liver (3 cc volume)
from data summed over 0–3, 10–15, and 15–20min. SUV
data for patients and HC were compared.
 Second: static images were created by summing data from
0–3min (3), 10–15min (10), and 15–20min (15).
 Third: ROIs drawn on the septal wall were used to cal-
culate mean, maximum, and minimum SUVs for each
set of summed data. SUV ratios were then calculated for
(0–3min)/(10–15min) (3:10) and (0–3min)/(15–20min)
(3:15) to assess the potential of a simple ratiometric method
for determining the presence of cardiac amyloidosis.
 Fourth: TAC data were used to determine the greatest range
between SUVmaxima and minima within the 20min imag-
ing time frame. Analysis of TAC data was used to assess the
maximum SUV within the first 3min of imaging as well as
minimum values between 10–15 and 15–20min. Ratios of
maximum to minimum SUV for each range of times were
then calculated.
Left and right ventricular variation of 18F-Florbetapir uptake
was assessed using both intra- and inter-patient observations.
Both of these were performed to assess the data for potential
differences in ventricular uptake in each individual and between
confirmed cardiac amyloid patients and healthy controls.
2.4. Rubidium PET/CT Imaging Protocol
Patients were injected with approximately 5mCi of 82Rb-Chloride
using a Cardiogen-82 rubidium generator and injection system
(Bracco, Prairie, MN, USA). Image data were acquired for 7min
with dynamic processing into 16 frames per routine clinically
used standards (25). As this perfusion study was only to measure
impact on resting 18F-Florbetapir uptake, patients were only asked
to perform the test at a resting heart rate and were not subjected to
undue pharmacological stress testing. This would have only been
appropriate if we were attempting to determine changes in heart
function between stress and rest.
All dynamic PET data were corrected for attenuation and scat-
ter using a low-dose CT protocol of 120 kVp and continuously
modulated mAs. CT data were not used for analysis of the per-
fusion data. Corrected data were reconstructed using an itera-
tive OSEM algorithm to create a 200 200 matrix with 2.05mm
isotropic voxels and 5mm slice thickness.
2.5. 82Rubidium Image Analysis
Adding to the current body of cardiac amyloid work using 82Rb-
Chloride compared to 18F-Florbetapir, analysis of myocardial
blood flow was performed using the FlowQuant software package
(Ottawa Heart Institute, Ottawa, ON, Canada). This software is
widely considered as a gold standard for cardiac image analysis
and has been thoroughly validated against common perfusion
analysis software used clinically (26, 27). The automated algo-
rithms and workflows in this software were used for reorientation
and segmentation of the heart. Visual confirmation was used
throughout the process to validate the placement of regions of
interest used for modeling or make adjustments with the selec-
tion. Partial volume corrections were applied to image derived
input functions drawn in the left ventricle to improve quantitative
accuracy in these small regions.
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2.6. Statistical Analysis
A comparison of myocardial blood flow results from 82Rb-
chloride modeling analysis and quantitative analysis from 18F-
Florbetapir was performed to determine any potential correlation
between 18F-Florbetapir uptake and decreased heart function as a
result of amyloid disease. Pearson correlation analysis was used
to assess the correlation between myocardial blood flow and
cardiac amyloid burden with p< 0.05 considered significant for
all statistical tests in this work. Confidence intervals (CI) of 95%
were calculated and discriminant function analysis (DFA) was
used to assess themodels ability to stratify patient populations and
determine the fit of the model to the data. Post hoc power analysis
was performed to assess statistical power where applicable.
In addition to our correlation of 82Rb-Chloride perfusion
to 18F-Florbetapir uptake, we assessed any potential correlation
between left ventricular mass and 18F-Florbetapir uptake. Left
ventricular mass was calculated using the formulation by Dev-
ereux et al. (28) and correlation analysis performed between LV
mass and 18F-Florbetapir maximum and mean activity concen-
trations in the myocardial regions of interest. Statistical correla-
tion analysis was performed by calculating Spearman correlation
coefficients.
3. Results
3.1. 18F-Florbetapir Cardiac Analysis
Visual assessment of static 18F-Florbetapir images showed differ-
ences between HC and patients with cardiac amyloidosis in the
form of increased uptake in regions of the heart associated with
amyloid burden (Figure 1). Accurate visual assessment was highly
dependent upon the imaging time frames used.
Analysis of myocardial TACs revealed significant differences
(p< 0.05) in estimates of washout rates for patients with cardiac
amyloid and HCs (Figure 2). Multi-exponential fits indicated
an increased uptake rate for HC as compared to patients with
calculated rates of 0.392 and 0.075min 1, respectively.
Most noticeable was the difference in uptake rates between 0
and 20min post injection (p.i.), where the average rate of change of
SUV for HC was 5.4 SUV/min as compared to 0.28 SUV/min for
amyloid patients [t(9)= 5.96, p< 0.01]. SUVs calculated using
ROIs drawn on summed 5min frames starting at 10 or 15min
p.i. showed statistically significant (p< 0.05) difference between
the mean SUV for patients and HC (Table 2). SUVmeasurements
at 10min p.i. provided the largest difference between amyloid
patients and HC (Table 3). None of the HC had an SUV >2
at 10 or 15min p.i. Assessment of correlation between activity
FIGURE 1 | Shows a 20-min acquisition of healthy (A) and amyloid
positive (B) patients. Both images were acquired at 1 h post injection.
concentration and left ventricularmass yielded no significant rela-
tionships with p> 0.05 for all calculations of Pearson and Spear-
man correlation coefficients. Post hoc power analysis indicated a
power of>90%.
No differences in left and right ventricular uptake were
observed between in any single patient or when comparing
healthy controls and those with confirmed cardiac amyloid dis-
ease (p< 0.05). No significant uptake was found in the ventricles
with SUVs of no more than three for any patient in our study
after peak values were reached within the first 3min of data
acquisition.
3.2. 18F-Florbetapir Analysis: Discriminant
Function Analysis
Discriminant function analysis verified that use of SUV alone at
10 and 15min time points created a statistically significant model
for patient stratification even in the small population used in
this study. Use of 95% CI classification methods did not work
as a useful model for the 15-min time point but was an accurate
classification method for the 10-min time point data. Differences
in ratios calculated for healthy and disease populationswere statis-
tically significant (p< 0.005) for all ratio methods tested as shown
in Table 4.
Discriminant function analysis verified that ratios of SUVs at
3:10 and 3:15min correctly classified all of the patient population
tested (n= 10) and was a statistically significant (p< 0.01) model.
The 3:10min ratio resulted in a greater canonical correlation
FIGURE 2 | Shows average myocardial TACs for healthy and amyloid
positive populations.
TABLE 2 | SUV measurements at different time points.
Subjects 3min SUVAvg 10min SUVAvg 15min SUVAvg
Healthy controls 8.70.6 1.70.3 1.40.2
Amyloid 8.44.4 6.11.6 4.71.7
TABLE 3 | SUV ratio values.
Subject 3:10min ratio 3:15min ratio
Healthy controls 5.120.99 6.20.95
Amyloid 1.40.6 2.31.4
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TABLE 4 | t-Test results for SUV ratios.
t-Score Sig. (2-tailed) Mean difference SE difference 95% Confidence interval of the difference
Lower Upper
t-Test for equality of means
3:10 TAC 9.15 0 7.03 0.77 5.26 8.8
3:10 Mean 7.25 0 3.7 0.51 2.52 4.87
3:15 TAC 6.34 0 7.66 1.21 4.87 10.44
3:15 Mean 5.84 0 4.2 0.72 2.54 5.85
FIGURE 3 | Shows boxplots of SUV ratios for all healthy and amyloid
positive patient groups.
(93.2%) as compared to the 3:15 ratio, which resulted in a 90%
correlation indicating that either time point ratio of static SUVs
would be a suitable model to classify the data. Lower threshold
limits for SUV mean ratios for 3:10 and 3:15 ratios were 4.7 and
5.3, respectively.
3.3. 18F-Florbetapir Analysis: Ratio Methods
Ratio methods derived from seeking maximum and minimum
values within the regions of interest of a given time frame yielded
similar results able to classify samples with >90% accuracy with
statistical significance (p< 0.001). Models using these maximized
ratios improved canonical correlation of the model to the data
compared to using only the mean SUVs from static images.
Maximized ratios of 3:10 and 3:15min resulted in canonical cor-
relations of 95.5% (2.4% increase) and 91.3% (1.4% increase),
respectively. Post hoc power analysis indicated a power of>90%.
In addition to DFA, ratio thresholds were assessed using the
95% CI of the mean or mean 2SD method. This simpler, but less
rigorous method also resulted in classification of>90% of disease
population vs. healthy controls for all ratio models calculated.
Boxplots (Figure 3) show the CIs for control and amyloid positive
groups further verifying statistical separation using this analysis
methodology.
FIGURE 4 | Shows liver TACs for average values of healthy control and
amyloid positive groups.
FIGURE 5 | Shows a comparison of liver uptake in healthy and
diseased populations. These images show that using the liver as a
reference point for quantitative measurements is risky as significant uptake is
seen even in healthy controls. This is further exacerbated as TAC
comparisons between TTR and controls are nearly indistinguishable.
3.4. 18F-Florbetapir Liver Analysis
Liver analysis indicated clearly separated TACs for healthy vs.
diseased populations when all data were averaged (Figure 4).
More detailed analysis of TTR and AL amyloid populations vs.
controls showed that TACs for TTR and control groups were
very similar while data from AL amyloid patients (Figure 5) were
distinctly separated from the other two patient groups. Peak values
from TACmeasurements were 14.04 for amyloid positive patients
Frontiers in Cardiovascular Medicine | www.frontiersin.org May 2015 | Volume 2 | Article 235
Osborne et al. Cardiac amyloidosis imaging with 18F-Florbetapir
and 13.4 for healthy controls. The average difference between any
points on the TACs was only 1.52 SUV.
3.5. 82Rb-Chloride Analysis
Quantitative cardiac flow assessments for all patients resulted
in rest rates of 1.1–1.7. These results were verified by a board
certified radiologist trained in nuclearmedicine and cardiac image
interpretation to bewithin normal resting cardiac flow rate ranges.
Correlation analysis of flow to patient disease status yielded a non-
significant (p= 0.742) negative correlation. Assessments of corre-
lation between ratio methods and perfusion results yielded non-
significant (p 0.05) negative correlations for all tested methods.
These results indicate that no significant correlation was seen
between reductions in perfusion performance and uptake of 18F-
Florbetapir in cardiac amyloid disease.
4. Discussion and Conclusion
4.1. Study Summary and Novelty
In this work, we have built upon the foundational work byDorbala
et al. that used 18F-Florbetapir to aid in quantitative diagnosis
of patients with cardiac amyloidosis. Our primary objective in
this study was to develop and assess a clinically relevant quanti-
tative imaging protocol that could be used in routine evaluation
of cardiac amyloidosis. We have expanded on previous work by
including comparisons of Florbetapir cardiac uptake with clinical
perfusion studies and have defined a 20min study that uses a sim-
ple analysis technique. We believe this work provides additional
confirmation of the ability of Florbetapir to be used as a tool for
diagnosis and assessment of cardiac amyloidosis patients.
4.2. Comparison to Previous Work
4.2.1. Comparison to 11C-PiB PET
Previous studies using 11C-based compounds are made difficult
by a number of factors (19). First is that to access 11C-based
compounds are limited only to a very small number of sites pre-
venting widespread proliferation and use of compounds based on
that radioisotope. Second, PIB is not available widely for use in the
United States without an investigational new drug (IND) applica-
tion, which also severely hinders its widespread use throughout
the North American medical community. Third, and finally, the
assessment required to show differences between control and dis-
ease populations in this study required dynamic image acquisition
of 60-min and complex data modeling and analysis, which is not
practical for routine clinical imaging.
4.2.2. Comparison to Other 18F-Florbetapir Studies
Our visual assessments agree with, and confirm, previous car-
diac 18F-Florbetapir imaging work as we found visual differences
between static PET/CT images of HC and patients with MRI-
confirmed cardiac amyloidosis. Visual assessments indicated dif-
ferences between healthy controls and patients with cardiac amy-
loid involvement in as little as 10min after injection with only a
10min acquisition, although even in controls, some background
remains in the heart and is never fully cleared even after 80min of
uptake. Visual comparison of controls and disease populationswas
problematic at later time points. Adding to published results by
Dorbala et al. using 18F-Florbetapir (21), we found that the ability
to perceive and quantify these differences depended heavily on
the uptake time prior to acquisition, length of the acquisition, and
even window/level settings (Figure 6).
Data from this study also add support to the paradigm that 18F-
Florbetapir does not necessarily bind avidly to peripheral amyloid
but rather is washed-out from amyloid positive tissue at a slower
rate. This could be due to low-affinity interactions of the probe
with the amyloid fibrils. The transient retention of the probe
in amyloid tissue explains why small differences are observed
in visual assessments over long dynamic acquisition times. This
also potentially explains interesting results from previous whole-
body biodistribution studies performed using this compound
FIGURE 6 | Shows control and amyloid positive patient data imaged from three of the initial 0–80min acquisitions. Each image from left to right shows the
progression of time at approximately 5, 10, 30, and 60min intervals.
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(29); however, this is an area requiring additional study since
this compound was primarily developed for use in Aβ amyloid
imaging rather than peripheral AL or TTR amyloid (30).
We have extended our own work in this field as well as that by
previous authors (21–23) by creating a clinical protocol that can
be completed within 20min and is easily performed at any PET
center. Our proposed analysis enhances previous work by having
neither requirement for calculation of ratios between organs nor
analysis of blood pool TAC integrals. Our method uses only a
single region of interest examined at two time points creating a
simple method for analysis that can be used by any trained imag-
ing specialist. We have also provided full guidance on executing
this protocol in Section “Appendix” so that others may use this
protocol in their practice.
4.2.3. Study Limitations
Although this work has added details regarding quantitative
assessment of cardiac amyloid and potential stratification of AL
vs. TTR positive patients, we did not focus on any use of this com-
pound in early stage amyloid disease. Additional studies would be
required with very specific patient selection in order to determine
how adequate this compound is in terms of detecting the presence
of amyloid in very early stage patients or within small areas of
infiltration.
Our DFA and t-test analyses resulted in the statistical separa-
tion of all of our samples in this study; however, we have examined
only a small sample of patients. With this small population, even
with the high degree of statistical significance and power of our
studies, it is not possible to conclude that this model would con-
tinue to work for a large population of patients. Further trials are
needed to assess this model’s ability to diagnose a larger variety of
cardiac amyloidosis patients.
This protocol also showed potential for use of 18F-Florbetapir
imaging in the stratification of AL amyloid from ATTR amyloid
using liver and cardiac TACs. Contrary to previous work, our
observations from this study indicated statistical separation of
data between AL amyloid populations when compared to healthy
controls and ATTR amyloid patients, however, ATTR patients
were not statistically separated from healthy control. Our con-
tributions show that more data are needed to assess the most
appropriate analysis technique for accurate stratification of AL
from ATTR using this compound.
Our work is an important addition to the field as it documents
a clinically useful 20min imaging protocol and a simple analysis
method for the assessment of cardiac amyloid disease. Develop-
ment of these simple methods potentially enhances the ability
for this compound to be used routinely for assessment of cardiac
amyloidosis. More extensive clinical trials would be needed to
fully assess the benefit of this compound for identifying patients
with cardiac amyloidosis; however, our analysis of PET/CT image
data using 18F-Florbetapir both confirms previous work in this
field and provides important newmethods for diagnosing this rare
but fatal disease.
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Appendix
A.1. Clinical Protocol
A.1.1. Imaging
 Place patient on PET/CT imaging pallet
 Acquire topogram of patient for selection of thoracic scan
range
 Perform CT using institutional parameters
 Begin listmode acquisition and wait 5 s
 Inject patient with approximately 10mCi of 18F-Florbetapir
 Perform 20min PET listmode acquisition
 Histogram data into two 5min datasets: 0–5, 15–20min
 Reconstruct histogrammed data using identical parameters.
Additionally, if the clinical viewing software supports visualiza-
tion of dynamic data, the dataset may be histogrammed using the
following parameters:
Frame 1: 0–5min
Frame 2: 6–14min
Frame 3: 15–20min
The corresponding ROI analysis is then only performed on the
first and third frames. For non-listmode enabled scanners, the
scan may need to be divided into two distinct 5min acquisitions
separated by the appropriate time delay.
 first acquisition: 5min acquisition beginning at injection
 second acquisition: 5min acquisition beginning at 15min
p.i.
A.1.2. Analysis
 Draw an ROI of at least 1 cc volume in the septal wall on the
first time point image
 Copy the ROI to the second time point image.
 Calculate the ratio between the regions of interest.
In both cases, users should check for appropriate registration
between the two time points before performing the ROI ratio
analysis.
A.2. Study Imaging Parameters
This section outlines the imaging parameters for each modality
used in this study.
A.2.1. CT
 kVp: 120
 mAs: continuously modulated (CareDose, Siemens Medical
Solutions USA, Inc.)
 Scan range: thoracic region from upper lung to just below
dome of liver
 Contrast: non-contrast enhanced
 Slice thickness: 5mm slice thickness
 Reconstructed image matrix: 512 512
 Pixel size: approximately 1.5mm.
A.2.2. PET
 Acquisition type: listmode
 No. of beds: 1
 Scan time: 20min
 Injection: approximately 10mCi 18F-Florbetapir
 Reconstructed image matrix: 200 200
 Pixel size: approximately 2mm
 Reconstruction algorithm: OSEM+Resolution Recovery
(TRUEX, HD-PET, Siemens Medical Solutions USA, Inc.).
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